A new study published in the European Journal of Preventive Cardiology found that semaglutide, a drug used for diabetes and weight loss, reduces the risk of new-onset atrial fibrillation by 17%. The effect was even stronger with the oral form, suggesting added heart benefits beyond blood sugar and weight control.